Sugi Predict

Sugi Predict / Targets / MEF2D

MEF2D

Myocyte-specific enhancer factor 2D · Q14814 · MEF2D on Sugi Atlas →

7,942 patent compounds predicted against MEF2D, 4,936 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1411177 SCHEMBL1411177 0.56 18/20
SCHEMBL1411182 SCHEMBL1411182 0.56 18/20
SCHEMBL1411180 SCHEMBL1411180 0.50 18/20
SCHEMBL1410811 SCHEMBL1410811 0.55 17/20
SCHEMBL1410813 SCHEMBL1410813 0.55 17/20
SCHEMBL1410837 SCHEMBL1410837 0.51 13/20
SCHEMBL1410841 SCHEMBL1410841 0.51 13/20
SCHEMBL1410971 SCHEMBL1410971 0.51 12/20
SCHEMBL1410977 SCHEMBL1410977 0.51 12/20
SCHEMBL1410877 SCHEMBL1410877 0.49 12/20
SCHEMBL1410882 SCHEMBL1410882 0.49 12/20
SCHEMBL1410891 SCHEMBL1410891 0.49 11/20
SCHEMBL1410898 SCHEMBL1410898 0.49 11/20
SCHEMBL1410895 SCHEMBL1410895 0.45 11/20
SCHEMBL1064141 SCHEMBL1064141 0.68 10/20
SCHEMBL1064142 SCHEMBL1064142 0.68 10/20
SCHEMBL1064610 SCHEMBL1064610 0.66 10/20
SCHEMBL1064612 SCHEMBL1064612 0.66 10/20
SCHEMBL1064599 SCHEMBL1064599 0.64 10/20
SCHEMBL1064601 SCHEMBL1064601 0.64 10/20

Clinical trials — most relevant to MEF2D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation PHASE4COMPLETED
Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia PHASE1/PHASE2UNKNOWN
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis PHASE2COMPLETED
HIF-1α Stabilization As a Novel Therapeutical Approach for Sarcopenia. nanRECRUITING
2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy Children nanCOMPLETED
HIDRAdenitis Suppurativa and HEART Disease nanACTIVE_NOT_RECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy nanCOMPLETED
Muscle Wasting in Cancer (MWIC) nanCOMPLETED
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis nanRECRUITING
Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a nanCOMPLETED
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome nanCOMPLETED
Fetal Cardiac Remodeling in Singleton Pregnancies Conceived by Assisted Reproductive Technology (Biopsied and Non-Biopsied ICSI) Versus Those Normally Conceived nanUNKNOWN
PITA-HF: Feasibility, Safety, and Tolerability nanCOMPLETED
WISE CVD - Continuation (WISE HFpEF) nanRECRUITING
Impact of Radiofrequency Ablation on Left Ventricular Function in Supraventricular Tachyarrhythmias Patient Using Speckle Tracking Echocardiography nanUNKNOWN
Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery nanUNKNOWN
CCM Italian Registry nanUNKNOWN
Right Ventricular Echocardiography in caRdiac SurgEry nanCOMPLETED
Mitochondrial Substrate Utilization in the Diabetic Human Heart nanRECRUITING
Multidisciplinary Study of Right Ventricular Dysplasia nanCOMPLETED
Biomarkers and SNP-polymorphisms in Post-infarction Cardiac Remodeling nanCOMPLETED
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death nanCOMPLETED
T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease nanCOMPLETED
Timecourse of Immobilization Experiment nanCOMPLETED
Oxygen Transport in Normobaric vs. Hypobaric Hypoxia nanCOMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
Diet Intervention and GEnetic STudy (DIGEST-Pilot) nanUNKNOWN
The PRE-OP ENERGY Trial nanUNKNOWN
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MEF2D binder may also engage these)

ProteinNameSimilarity
O89038 — 1.000 O89038 →
Q63943 — 1.000 Q63943 →
A2ICN5 — 0.998 A2ICN5 →
Q80TZ9 — 0.998 Q80TZ9 →
Q9W6U8 — 0.998 Q9W6U8 →
A2VDZ3 — 0.998 A2VDZ3 →
Q62901 — 0.997 Q62901 →
Q7TN99 — 0.997 Q7TN99 →
Q96L91 — 0.997 Q96L91 →
Q5REW7 — 0.996 Q5REW7 →
Q95RW8 — 0.996 Q95RW8 →
Q2EJA0 — 0.996 Q2EJA0 →
Q2KIA0 — 0.996 Q2KIA0 →
TFEB Transcription factor EB 0.996 landscape →
Q58NQ4 — 0.996 Q58NQ4 →
Q9GZV5 — 0.996 Q9GZV5 →
Q05B92 — 0.995 Q05B92 →
Q02078 — 0.995 Q02078 →
Q60929 — 0.995 Q60929 →
P06537 — 0.995 P06537 →
P23899 — 0.995 P23899 →
Q91904 — 0.995 Q91904 →
Q03413 — 0.995 Q03413 →
Q9DE25 — 0.995 Q9DE25 →
A2D4R4 — 0.995 A2D4R4 →
Q6YHU8 — 0.995 Q6YHU8 →
Q8CFN5 — 0.995 Q8CFN5 →
Q80WT2 — 0.995 Q80WT2 →
Q9BG89 — 0.995 Q9BG89 →
P61753 — 0.995 P61753 →